Recap: NovoCure Q1 Earnings

 

Shares of NovoCure NVCR fell 2.7% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share were down 200.00% year over year to ($0.04), which missed the estimate of $0.02.

Revenue of $134,695,000 higher by 32.28% year over year, which missed the estimate of $139,360,000.

Looking Ahead

NovoCure hasn't issued any earnings guidance for the time being.

NovoCure hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Apr 29, 2021

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/ycx5povk

Technicals

Company's 52-week high was at $220.48

Company's 52-week low was at $55.40

Price action over last quarter: Up 34.14%

Company Profile

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!